Harbor Investment Advisory’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-3,899
Closed -$51.9K 1297
2023
Q2
$51.9K Buy
3,899
+263
+7% +$3.2K 0.01% 702
2023
Q1
$42.1K Hold
3,636
0.01% 755
2022
Q4
$29.7K Hold
3,636
﹤0.01% 817
2022
Q3
$21K Hold
3,636
﹤0.01% 899
2022
Q2
$16K Hold
3,636
﹤0.01% 947
2022
Q1
$33K Buy
3,636
+1,767
+95% +$20.3K ﹤0.01% 839
2021
Q4
$38K Buy
+1,869
New +$45.1K ﹤0.01% 817

Other funds holding PACB

Harbor Investment Advisory's PACB Position: Q3 2023 in Review

Harbor Investment Advisory sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 3,899 shares — an estimated $51.9K sold.

Harbor Investment Advisory first reported a position in PACB in Q4 2021 and held it in 7 quarters. The position peaked at $51.9K in Q2 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

  • Harbor Investment Advisory reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
  • Harbor Investment Advisory sold 3,899 Pacific Biosciences shares in Q3 2023, an estimated $51.9K.
  • Harbor Investment Advisory first reported a position in Pacific Biosciences in Q4 2021 and held it in 7 quarters.
  • Harbor Investment Advisory's Pacific Biosciences position peaked at $51.9K in Q2 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Harbor Investment Advisory's 13F filing for Q3 2023, filed 13 Oct 2023.